Dermata Therapeutics shares surge 40.91% intraday as stock crosses above 20-day SMA amid broader market gains.

Dermata Therapeutics surged 40.91% intraday following a 23.14% pre-market gain as the stock crossed above its 20-day simple moving average (SMA), signaling positive investor sentiment. The rally coincided with broader market gains, with the Nasdaq-100 and S&P 500 both rising slightly, suggesting a broader risk-on environment. Analysts attributed the momentum to optimism around Dermata’s product pipeline, particularly its XYNGARI and DMT410 candidates, and improved financial metrics, including lower-than-estimated operating expenses in Q2. Despite Maxim down.